Replies to post #106777 on Biotech Values

[DewDiligence]

It’s amusing that AVNR’s BoD includes the CEO’s of both MNTA and Regado, who are nominally competitors in the ACS arena.

[DewDiligence]

Congrats to Wheeler—FDA approves AVNR’s Nuedexta (f/k/a Zenvia) for pseudobulbar affect:

http://finance.yahoo.com/news/AVANIR-Pharmaceuticals-prnews-3924140648.html?x=0&.v=1

Nuedexta, which has had a checkered development history, was discussed on this board more than six years ago (e.g. #msg-3877326). The drug is a fixed-dose combination of two generics: quinidine and dextromethorphan.

CC Monday at 8:15 am ET.